Myriad Genetics Inc

MYGNNASDAQ • USD
ThemeGenomics & Precision Med.›Genetic Testing & Diagnostics
3.19 USD
↗ 0.14 (4.59%)AT CLOSE (11:59 AM EDT)
3.21
↗ 0.02 (0.63%)
POST MARKET (AS OF 07:43 PM EDT)
Post Market
AS OF 07:43 PM EDT
3.21
↗ 0.02 (0.63%)
🟢Market: OPEN

MYGN is currently priced at $3.21. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, MYGN appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Aug 25, 2026.

Open?$3.06
High?$3.21
Low?$3.01
Prev. Close?$3.05
Volume?1.8M
Avg. Volume?2.2M
VWAP?$3.15
Rel. Volume?0.81x
Bid / Ask
Bid?$3.02 × 100
Ask?$3.22 × 100
Spread?$0.20
Midpoint?$3.12
Valuation & Ratios
Market Cap?291.7M
Shares Out?95.6M
Float?90.9M
Float %?96.2%
P/E Ratio?N/A
P/B Ratio?0.96
EPS?-$1.18
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Themes
Healthcare - Genomics & Precision Medicine›Genetic Testing & DiagnosticsHealthcare - Oncology›Cancer Diagnostics & Biomarkers
Employees
2.7K
Market Cap
291.7M
Industry
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Website
www.myriad.com
Listed
1995-10-06
Address
322 NORTH 2200 WEST
SALT LAKE CITY, UT 84116
Phone: 801-584-3600
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
1
Momentum?
17
Short Sent.?
51
Piotroski F-Score?3/9Weak
Altman Z-Score?-1.06Distress
Confidence?62%Moderate
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?8.45%Elevated
Short Interest?7.7M
Days to Cover?3.0
Free Float90.9M
Avg Daily Volume2.6M
Settlement Date2026-08-14
Financial Health
Current Ratio?2.21Strong
Quick Ratio?1.98Adequate
Cash Ratio?0.88Adequate
Debt/Equity?0.40Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.96CHEAP▾
P/S?
Peers
100
S&P
97
0.36CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-7.4CHEAP▾
EV/Sales?
Peers
100
S&P
97
0.37CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-37.1%WEAK▾
ROA?
S&P
3
-17.6%WEAK▾
Cash Flow & Enterprise
FCF?$-7300000
Enterprise Value?$297.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist